Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

BACKGROUND AND AIM: Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection. HEP3002 is an ongoing multinational programme to evaluate safety and efficacy of telaprevir (TVR) plus pegylated-interferon-...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombo, M, Fernández, I, Abdurakhmanov, D, Ferreira, P A, Strasser, S I, Urbanek, P, Moreno, C, Streinu-Cercel, A, Verheyen, A, Iraqi, W, DeMasi, R, Hill, A, Läuffer, J M, Lonjon-Domanec, I, Wedemeyer, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078754/
https://www.ncbi.nlm.nih.gov/pubmed/24201995
http://dx.doi.org/10.1136/gutjnl-2013-305667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078754/
https://www.ncbi.nlm.nih.gov/pubmed/24201995
http://dx.doi.org/10.1136/gutjnl-2013-305667

Ejemplares similares